Alkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease.
Alkermes plc Reports Third Quarter Fiscal 2012 Financial Results Read More
Alkermes Initiates Open-Label Pilot Study of VIVITROL® to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence Read More
FDA Approves BYDUREON™ -- The First and Only Once-Weekly Treatment for Type 2 Diabetes Read More
Learn More 
